RDPAC's Lobbying Efforts To Regulate China's Medical Representatives Likely To Pay Off This Year
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - As China rolls out its 12th five-year economic development plan, the R&D-based Pharmaceutical Association Committee (RDPAC) - an industry association representing multinational biopharma companies in China - is suggesting a friendlier regulatory environment for foreign companies